Screening Colonoscopy and EHRs Significantly Decrease Risk of CRC

Share this content:
Screening May Reduce Risk for Late-Stage CRC by 70 Percent
Screening May Reduce Risk for Late-Stage CRC by 70 Percent

(HealthDay News) -- For average-risk adults, screening colonoscopy is associated with a significant decrease in the risk of any colorectal cancer (CRC) and of right colon cancer; and interventions using electronic health records (EHRs) increase screening rates, according to two studies published in the March 5 issue of the Annals of Internal Medicine.

Chyke A. Doubeni, M.D., M.P.H., of the University of Pennsylvania in Philadelphia, and colleagues examined the effectiveness of screening colonoscopy using data from 1,039 average-risk adults enrolled in four U.S. health plans. In analyses restricted to 471 eligible case patients and 509 matched controls, the researchers found that 2.8 percent of case patients and 9.0 percent of controls had undergone screening colonoscopy (adjusted odds ratios, 0.29 for any late-stage CRC; 0.36 for right colon cancer; and 0.26 for left colon/rectum cancer). The odds of overall CRC and left colon cancer, but not right colon cancer, were significantly reduced with sigmoidoscopy.

Beverly B. Green, M.D., M.P.H., of the University of Washington School of Medicine in Seattle, and colleagues assessed whether interventions using EHRs, automated mailings, and stepped increases in support improved adherence to CRC screening over two years among 4,675 adults aged 50 to 73 years not current for CRC screening. The interventions included usual care; EHR-linked mailings; EHR-linked mailings with telephone assistance; or EHR-linked mailings, telephone assistance, and nurse navigation. The researchers found that participants in intervention groups were significantly more likely to be current for CRC screening for both years, compared with usual care.

"Compared with usual care, a centralized, EHR-linked, mailed CRC screening program led to twice as many persons being current for screening over two years," Green and colleagues write. "Assisted and navigated interventions led to smaller but significant stepped increases compared with the automated intervention only. The rapid growth of EHRs provides opportunities for spreading this model broadly."

Full Text - Doubeni (subscription or payment may be required)
Full Text - Green (subscription or payment may be required)

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs